Table 1. . Clinical trials of immunotherapy in early-stage breast cancer.
| Phase | Study | Vaccine type | NCI identifier | Status |
|---|---|---|---|---|
| I | Folate receptor binding peptide vaccine | Peptide/protein | NCT02019524 | Open |
| I | GP2-GM-CSF versus AE37 + GM-CSF versus GM-CSF alone | Peptide/protein | NCT00524277 | Open |
| I | NY-EOS-1 vaccine + sirolimus | Peptide/protein | NCT01522820 | Open |
| I | MUC1-peptide for triple-negative breast cancer | Peptide/protein | NCT00986609 | Open |
| II | Trastuzumab + GM-CSF/HER-2 E75 peptide | Peptide/Protein | NCT01570036 | Open |
| III | NeuVax TM | Peptide/protein | NCT01479244 | Open |
| I | Pilot-breast cancer vaccine + Poly-ICLC | Celullar vaccine | NCT01532960 | Open |
| II | GSK2302024A (Wilms tumor 1-specific therapy) + adjuvant therapy | Celullar vaccine | NCT01220128 | Open |
| II | Preoperative cryotherapy +/- ipilimumab (anti-CTLA-4) | Checkpoint inhibitors | NCT01502592 | Open |
| I/II | HER-2/Neu-pulsed DC1 vaccine combined with trastuzumab for patients with DCIS | Pulsed dentritic cells | NCT02336984 | Open |
| I/II | Randomized trial of HER-2/Neu-pulsed DC1 vaccine for patients with DCIS | Pulsed dentritic cells | NCT02061332 | Open |
| I/II | Nelipepimut-S E75 (HER2) NeuVax TM | Peptide/protein | Closed | |
| I/II | GP2 + GM-CSF | Peptide/protein | Closed | |
| AE37 + GM-CSF | Peptide/protein | Closed | ||
| AE37/GP2 + GM-CSF | Peptide/protein | Closed | ||
| I | A HER-2/Neu-pulsed DC1 vaccine for patients with DCIS | Pulsed dentritic cells | NCT00107211 | Closed |
DCIS: Ductal carcinoma in situ; MUC-1: Mucin-1.